TY - JOUR AU - Seiwert, T Y TI - Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial JO - Lancet Oncol VL - 17 PY - 2016 DO - 10.1016/S1470-2045(16)30066-3 L3 - PubMed-ID: 27247226 SP - 956 EP - 965 N1 - et al. ER -